INTRODUCTION
============

Pre-eclampsia (PE) is characterized by new-onset hypertension and proteinuria at ≥20 weeks of gestation \[[@sfz025-B1]\]. This human-specific syndrome affects 2--8% of all pregnancies, and is a leading cause of maternal and perinatal morbidity and mortality \[[@sfz025-B2]\]. Superimposed PE (SPE) is the development of PE in a patient with chronic hypertensive vascular or renal disease \[[@sfz025-B3]\]. Women with chronic kidney disease (CKD) are at increased risk of SPE, reported to occur in 22--75% of pregnancies \[[@sfz025-B4]\]. Diagnosis of SPE using arterial hypertension and proteinuria is difficult and of limited clinical use because both may pre-exist in women with CKD even without SPE \[[@sfz025-B5]\]. Inaccurate diagnosis may lead to unnecessary iatrogenic preterm delivery.

The renin--angiotensin--aldosterone system (RAAS) is known to be an important regulator of blood pressure, sodium and fluid homeostasis. Angiotensinogen (AGT) is the only substrate for renin, which cleaves a 10 amino acid peptide from its N-terminus, angiotensin I (Ang I), which is subsequently cleaved to the biologically active Ang II \[[@sfz025-B6]\]. Ang II binds to specific receptors, triggering a broad range of biological actions impacting virtually every organ in the body. Ang II also stimulates the secretion of the hormone aldosterone from the adrenal cortex \[[@sfz025-B7]\]. Aldosterone causes the tubular epithelial cells of the kidneys to increase the reabsorption of sodium ions from the tubular fluid back into the blood, while at the same time causing them to excrete potassium or hydrogen ions into the tubular fluid, which will become urine. Tetrahydroaldosterone (TH-aldo) is the major metabolite of aldosterone, and its urinary excretion is used to estimate aldosterone secretion. Plasma and urinary aldosterone concentrations are elevated, while plasma renin activity and Ang II are reduced, in patients with CKD \[[@sfz025-B8], [@sfz025-B9]\].

A healthy pregnancy involves both renal and systemic haemodynamic adaptations, which allow continual renal retention of sodium and water and substantial, cumulative, plasma volume expansion from very early in gestation; these changes are all 'physiological' in pregnancy and are a result of the activation of the RAAS \[[@sfz025-B10], [@sfz025-B11]\]. In PE, plasma volume expansion has been reported to be 13% lower than in normal pregnancy and this precedes increases in blood pressure \[[@sfz025-B12], [@sfz025-B13]\]. In women with established PE, plasma aldosterone, renin and Ang II concentrations are all suppressed compared with normotensive pregnant controls \[[@sfz025-B14]\]. However, an intriguing prospective study in 1969 \[[@sfz025-B19]\] suggested second-trimester activation of the RAAS, both basally and in response to sodium depletion, in women who went on to develop 'toxaemia', but this response has never been validated.

Placental growth factor (PlGF) is an angiogenic protein synthesized primarily by syncytiotrophoblasts, which increases in the blood of normotensive pregnant women until 26--30 weeks of gestation and then falls towards term \[[@sfz025-B20]\]. Low PlGF concentrations have been reported in women with PE, possibly due to the rise in soluble fms-like tyrosine kinase-1 (sFlt-1), an anti-angiogenic soluble protein that binds PlGF \[[@sfz025-B21]\], thus preventing interaction with endothelial receptors. Recently, we have shown that PlGF could be used as a potential marker to assist clinical decision-making in women with SPE \[[@sfz025-B22]\]. We and others have also previously reported PlGF associations with the components of the RAAS \[[@sfz025-B23], [@sfz025-B24]\]; in particular, aldosterone can stimulate PlGF in placental (BeWo) and adrenocortical (H295R) cell lines \[[@sfz025-B24]\].

We hypothesized that altered concentrations of RAAS components and lower PlGF concentrations would discriminate pregnant women with CKD alone from those with CKD and SPE. The aim of the study was to compare plasma active renin, total plasma and urinary AGT, urinary TH-aldo and plasma PlGF concentrations in pregnant White European women with CKD with and without SPE, and in normotensive pregnant controls and women with PE without pre-existing disease.

MATERIALS AND METHODS
=====================

Cohort and sample collection
----------------------------

Samples were obtained from participants who were recruited to a multicentre (Imperial College and King's Health Partners) study of a PE, CKD and SPE cohort between June 2009 and September 2013, following written informed consent. Full details of definitions of each group can be found in a previous report \[[@sfz025-B22]\]. A pragmatic approach was adopted; all samples from White European women that were available for analysis within the cohort were selected and analysed, and all data presented. Due to the known differences in the RAAS in Afro-Caribbean women \[[@sfz025-B25]\], only White European women were selected. The groups that were examined consisted of pregnant normotensive control (NC) participants (*n* = 20) and pregnant women with PE (*n* = 9), normotensive CKD without SPE (CKD; *n* = 8) and SPE (on background of CKD; *n* = 11) as defined previously \[[@sfz025-B22]\] and summarized in [Table 1](#sfz025-T1){ref-type="table"}. Exclusion criteria were age \<18 or \>50 years, an inability or unwillingness to give informed consent, known HIV, Hepatitis B or C positive or a multi-foetal pregnancy. Ethical approval was provided by the National Research Ethics Service (11/LO/1776), and the study was performed in accordance with the guidelines of the Declaration of Helsinki.

###### 

Definitions used for classification of women---adapted from \[[@sfz025-B22]\]

  Definition         Criteria
  ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCs                • No risk factors for PE; • no history of PE, hypertension, diabetes mellitus, renal disease, connective tissue disease or anti-phospholipid antibody syndrome; • systolic blood pressure \<140 mmHg; • diastolic blood pressure \<90 mmHg; • no or trace protein or less on dipstick analysis of midstream urine; • not in labour
  PE                 • Gestational hypertension (≥140/90 mmHg after 20 weeks' gestation) AND proteinuria of \>300 mg protein over 24 h (or protein:creatinine ratio of \>30 mg/mmol)
  Normotensive CKD   According to the Kidney Disease Outcomes Quality Initiative guidelines before pregnancy (Guidelines, 2012) \[[@sfz025-B28]\]OR Persistent proteinuria \[\>30 mg/mmol (protein:creatinine ratio)\] at \<20 weeks of gestation in the absence of urinary tract infectionOR Any recorded serum creatinine \>70 μmol before 20 weeks' gestation without risk factors for acute kidney injury
  SPE                Two recordings of systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg \>4 h apart after 20 weeks' gestationOR Additional features as listed above

Venous blood samples were collected in the third trimester (\>28 weeks of gestation) and plasma aliquots stored at −80°C. Midstream urine samples were collected into sterile containers, centrifuged at 1400 g (10 min), and stored in multiple aliquots at −80°C within 3 h of collection.

Assay analyses
--------------

All samples were analysed masked to clinical outcome.

### Plasma active renin concentrations

Plasma active renin concentrations were assayed, blinded to outcome, in duplicate by enzyme-linked immunosorbent assay (ELISA) (IBL, Hamburg, Germany). Intra- and inter-assay coefficients of variation were 4 and 11.6%, respectively.

### Plasma and urine AGT concentrations

Plasma and urine AGT concentrations were measured, blinding to outcome group, in duplicate by ELISA (IBL, Japan). Plasma samples were diluted 1:10 000 and urine samples between 1:4 and 1:30, using buffer provided within the kit. Intra- and inter-assay coefficient of variation for plasma were 4.2 and 14.1% and for urine were 4.8 and 11.6%, respectively.

### Plasma PlGF concentrations

PlGF was measured in plasma samples for a previous larger study \[[@sfz025-B22]\]. Briefly, plasma samples were analysed using the Triage PlGF kit (Alere, San Diego, CA, USA). The assay used a fluorescently labelled recombinant murine monoclonal antibody, with the range of detection of between 12 and 1300 pg/mL. The coefficient of variations for standard controls (85 and 1300 pg/mL) was 12.8 and 13.2%, respectively.

### Urinary aldosterone

Urinary TH-aldo was analysed by gas chromatography-mass spectrometry (GC-MS) according to a modified method, originally described by Shackleton \[[@sfz025-B29]\] and applied by us as reported earlier \[[@sfz025-B30]\]. Measurement of TH-aldo rather the aldosterone was conducted as we used the mass spectrometry-based assays that are able to accurately measure individual steroid hormone concentrations. Many of the conventional assays for aldosterone, such as the radioimmunoassays and ELISAs, are compromised by significant cross-reactivity and lack of specificity \[[@sfz025-B30]\].

Sample preparation consisted of pre-extraction, enzymatic hydrolysis, extraction from the hydrolysis mixture, derivatization and gel filtration. Medroxyprogesterone (2.5 μg) was added as recovery standard to 1.5 mL urine. The sample was extracted on a Sep Pak C18 column, dried, reconstituted in 0.1 M acetate buffer (pH 4.6) and hydrolysed with powdered Helix pomatia enzyme (12.5 mg) and 12.5 μL of *β*-glucuronidase/arylsulfatase liquid enzyme at 55°C for 3 h. The resulting free steroids were extracted on a Sep Pak C18 cartridge and 0.15 μg of 3β5β-TH-aldo was added as a standard for derivatization and chromatography. The samples were derivatized to form methyloxime-trimethylsilyl ethers. The derivatives were purified by gel filtration on Lipidex 5000 columns. Samples were analysed on a gas chromatograph 6890 N equipped with a mass selective detector 5973 N (Agilent, La Jolla, CA, USA) during a temperature-controlled run over 35 min by selected ion monitoring. One specific ion was monitored for each compound analysed. A known amount of 3α5β-TH-aldo was measured on a regular basis to act as a calibration standard. The recovery of the analysis was checked with medroxyprogesterone and results were corrected for the loss during sample preparation; all samples had recoveries \>80%. The urinary concentration of 3α5β-TH-aldo was normalized against urinary creatinine concentration.

### Urinary creatinine

Urinary creatinine concentrations were measured with the enzymatic creatinine method (Roche Diagnostics Inc.).

Statistical analysis
--------------------

All tests were performed using SPSS version 22. Summary data are presented as means±standard deviation (SD) or median and interquartile range (IQR) as appropriate. The Kruskal--Wallis test followed by Mann--Whitney U-test was used for multiple group analysis. The Student's *t*-test or Mann--Whitney U-tests were used depending on the distribution of the data, after testing using the Kolmogorov--Smirnov test. The null hypothesis was rejected where P \< 0.05.

RESULTS
=======

Baseline demographic and pregnancy outcome data are presented in [Table 2](#sfz025-T2){ref-type="table"}. There were no demographic differences between women with CKD, who did or did not experience SPE other than significantly lower blood pressures compared with women with SPE (P* *\<* *0.05). Further detailed data regarding the whole cohort have been previously published \[[@sfz025-B22]\].

###### 

Participant demographics and pregnancy outcome data

  Parameter                                                                            NC (*n*=20)                             PE (*n*=9)                     CKD without SPE (*n*=8)                                        SPE (*n*=11)
  ------------------------------------------------------------- ---------------------------------------------------------- ------------------- ------------------------------------------------------ -----------------------------------------------------------
  Age at booking, mean ± SD, years                                                      31.0 ± 6.9                             30.0 ± 6.7                            36.0 ± 7.1                                               33.0 ± 4.7
  BMI at booking, mean ± SD, kg/m^2^                                  24.0 ± 5.9[^a^](#tblfn1){ref-type="table-fn"}            32.4 ± 8.1                            30.3 ± 7.6                                               27.2 ± 4.1
  Nulliparous, *n* (%)                                                                   13 (68)                                 5 (63)                                3 (60)                                                   8 (73)
  CKD Stage, *n* (%)                                                                        --                                     --              Stage 1: 4 (50)Stage 2: 3 (38)Stage 3: 1 (12)       Stage 1: 8 (73)Stage 2: 1 (9)Stage 3: 1 (9)Stage 4: 1 (9)
  ≥2+ proteinuria at booking                                                                --                                     --                                  3 (38)                                                   2 (18)
  Serum creatinine (µmol/L)                                                                 --                                     --                               72 (64, 81)                                               59 (44, 81)
  Smoking, *n* (%)                                                                        7 (35)                                 1 (11)                                4 (50)                                                   3 (27)
  Gestational age at sampling, median (IQR), weeks               35.0 (33.0--37.3)[^a^](#tblfn1){ref-type="table-fn"}^,b^   36.6 (35.1--38.3)   37.5 (36.4--38.7)[^d^](#tblfn4){ref-type="table-fn"}                       33.0 (27.6--34.4)
  Caesarean section, *n* (%)                                                              2 (10)                                 6 (67)                                3 (38)                                                   8 (73)
  Highest SBP, mean ± SD, mmHg                                     110 ± 11.7[^a^](#tblfn1){ref-type="table-fn"}^,b,c^         149 ± 10.1          123 ± 13.1[^d^](#tblfn4){ref-type="table-fn"}                              150 ± 14.1
  Highest DBP, mean ± SD, mmHg                                      68 ± 7.5[^a^](#tblfn1){ref-type="table-fn"}^,b,c^           96 ± 7.1                             87 ± 13.5                                                 97 ± 5.3
  Highest 24-h urine collection protein, median (IQR), g/24 h                               --                               0.7 (0.4--1.2)                        0.2 (0.2--0.6)                                           0.5 (0.3--0.7)
  Highest protein urine PCR, median (IQR)                                                   --                                 47 (25--92)                          91 (13--213)                                             115 (83--280)
  Gestational age at delivery, median (IQR), weeks               40.0 (39.6--40.6)[^a^](#tblfn1){ref-type="table-fn"}^,b^   38.0 (37.4--38.7)   39.4 (37.4--38.7)[^d^](#tblfn4){ref-type="table-fn"}                       36.6 (34.0--38.0)
  Birth weight, median (IQR), g                                  3505 (3150--3910)[^a^](#tblfn1){ref-type="table-fn"}^,b^   2960 (2200--3120)                    3325 (3190--3915)                                         2390 (1584--3050)
  Birth weight centile, median (IQR)                                                 49.5 (30.5--64)                         23.0 (14.5--42)                      30.5 (22.5--44)                                          14.0 (6.5--56.5)

P \< 0.05 between NCs and PE.

P* *\<* *0.05 between NCs and SPE.

P* *\<* *0.05 between NCs and CKD.

P* *\<* *0.05 between CKD and SPE. BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; PCR, protein:creatinine ratio.

Urine TH-aldo:creatinine ratios and plasma active renin (Kruskal--Wallis, both P \< 0.05) were significantly different between groups. TH-aldo:creatinine ratios were significantly lower in both PE and SPE compared with the NC and women with CKD without SPE (P \< 0.05 for all; [Figure 1A](#sfz025-F1){ref-type="fig"}).

![Maternal (**A**) urinary aldosterone; (**B**) plasma active renin; (**C**) urinary AGT concentrations; and (**D**) plasma AGT concentrations in women with an NC pregnancy, PE pregnancy, CKD without SPE or CKD with SPE. Data represented as median (IQR) with outliers shown as symbols (filled circle); \*P* *\<* *0.05.](sfz025f1){#sfz025-F1}

Plasma active renin concentrations were also lower in PE and SPE women compared with NC women (P \< 0.05 for all; [Figure 1B](#sfz025-F1){ref-type="fig"}). In addition, the SPE women had significantly lower concentrations compared with the CKD women who did not develop SPE ([Figure 1B](#sfz025-F1){ref-type="fig"}), but there were no differences between women with CKD alone and PE.

Urinary total AGT:creatinine ratios were significantly different between groups (Kruskal--Wallis, P \< 0.05); levels were higher in PE compared with NC (P* *=* *0.03). Interestingly, urinary total AGT:creatinine ratios in women with SPE were significantly lower than women with PE (P* *=* *0.01); no differences were found between the CKD group and all other groups (P \> 0.05; [Figure 1C](#sfz025-F1){ref-type="fig"}).

Although women with PE appeared to have lower plasma AGT concentrations than NC, no significant differences were seen between groups (Kruskal--Wallis, P* *\>* *0.1; [Figure 1D](#sfz025-F1){ref-type="fig"}).

The Kruskal--Wallis test indicated a highly significant difference in plasma PlGF concentrations (P* *\<* *0.0001; [Figure 2](#sfz025-F2){ref-type="fig"}) between groups. Subsequent Mann--Whitney U-tests confirmed that PlGF concentrations were significantly lower in both women with PE and SPE compared with the NC and CKD women, respectively (P \< 0.05 for all; [Figure 2](#sfz025-F2){ref-type="fig"}).

![Maternal plasma active PlGF concentration in women with a NC pregnancy, PE pregnancy, CKD without SPE or CKD with SPE. PlGF was measured in plasma samples from a previous larger study \[[@sfz025-B22]\]. Data represented as median (IQR) with outliers shown by symbols; \*P* *\<* *0.05; \*\*P* *\<* *0.001; \*\*\*P* *\<* *0.0001.](sfz025f2){#sfz025-F2}

DISCUSSION
==========

The novel finding in this study is that women with CKD with SPE have reduced urinary TH-aldo excretion and plasma active renin concentration compared with those with CKD without SPE. This parallels previous observations that women with PE without pre-existing disease have suppressed RAAS activation compared with NCs. During pregnancy, there is a 30--50% expansion in extracellular fluid and a 30--40% increase in plasma volume, which is an essential component of pregnancy-associated augmentation in organ perfusion \[[@sfz025-B31]\]. The RAAS is activated very early in pregnancy, proposed to be a consequence of the 'underfilling' of the circulation \[[@sfz025-B10]\] and leading to water and sodium retention. Plasma volume expansion is less pronounced in women who subsequently develop PE without pre-existing disease and a decreased expansion can be detected as early as Weeks 14--17 of gestation \[[@sfz025-B32]\], although it is not known whether this is primary or secondary.

Plasma active renin concentrations are elevated in healthy pregnancy, probably as a compensatory mechanism in response to the fall in vascular resistance and blood pressure at the beginning of pregnancy. Renin synthesis has been demonstrated to be suppressed in women with established PE \[[@sfz025-B15]\]. Interestingly, a small (*n* = 58), but prospective, study reported non-significant activation of the RAAS between Weeks 13 and 27, both basally and in response to sodium depletion, in women who went on to develop 'toxaemia' although a majority of these women probably had (non-proteinuric) gestational hypertension \[[@sfz025-B33]\]. In addition, a recent study has also reported similar changes in the RAAS in patients with chronic hypertension and SPE \[[@sfz025-B34]\]. Furthermore, a study of plasma volume throughout pregnancy in initially normotensive women reported that in 29 of 40 women who subsequently developed hypertension, early volume expansion was followed by significant volume contraction in the third trimester, before blood pressure rose \[[@sfz025-B35]\]. It remains unclear why renin levels are low despite reduced plasma volume in women with established PE, but proposed mechanisms include elevated atrial natriuretic peptide concentrations in PE \[[@sfz025-B36]\], increased sensitivity to Ang II and AT1R-autoantibodies \[[@sfz025-B37]\] or reduced vascular endothelial growth factor (VEGF) availability, which has been shown to suppress renin \[[@sfz025-B38]\]. Low VEGF availability could also lead to impaired adrenal aldosterone release, secondary to changes in the fenestrated endothelium of the juxtaglomerular apparatus, which we have previously described \[[@sfz025-B39]\].

Reduced plasma active renin concentrations in women with both PE and SPE despite suppressed plasma active renin concentrations in women with CKD without SPE compared with NC suggest this reduction to be a consequence of the underlying pathophysiology of PE, and an appropriate response to the hypertension. This finding is in keeping with previous reports of maintained plasma renin activity in women who developed *de novo* gestational hypertension without significant proteinuria \[[@sfz025-B40]\]. However, a variety of animal studies of the (initially) subpressor infusion of Ang II either systemically or directly into the renal artery showed persistent changes in both systemic and renal resistance vasculature (see \[[@sfz025-B43]\]). This accords with Folkow's original suggestion in the 1950s that an apparently very small stimulus may be enough to trigger vascular hypertrophy and hypertension in susceptible individuals, which could be maintained after the stimulus ceased (see \[[@sfz025-B44]\]). By analogy with this, the early stimulation of the RAAS in all pregnancies might, in susceptible women, lead to vascular changes, which result in hypertension.

Urinary TH-aldo concentrations are also relatively lower in pregnancies complicated by PE compared with NCs and are likely to contribute to decreased volume expansion and subsequent poor placental perfusion. We have previously reported urinary TH-aldo levels to be correlated with placental weight and proliferation of cultured trophoblasts is increased upon aldosterone stimulation \[[@sfz025-B24]\]. Our finding that urinary TH-aldo: creatinine ratios are also lower in SPE compared with women with CKD who did not develop SPE further suggests that this finding is a PE-specific alteration. It is important to highlight that previous measurements of plasma aldosterone using radioimmunoassays or ELISA are hampered by high cross-reactivity with other metabolites, especially progesterone \[[@sfz025-B30]\], whereas the validated, highly sensitive GC-MS of the major metabolite, TH-aldo, used in this study resolves such issues. In addition, urinary excretion must be considered a better representation of the overall temporal exposure to aldosterone and AGT.

Lower PlGF concentrations in women with both PE and SPE compared with those with CKD without SPE and NCs is consistent with our previous findings \[[@sfz025-B22]\] and further highlights this as a useful diagnostic tool for both PE and SPE. The similar pattern of changes seen for PlGF with renin and aldosterone strengthens previously identified associations of PlGF and RAAS activation \[[@sfz025-B24], [@sfz025-B45]\]. Further work to fully elucidate mechanisms of regulation between angiogenic imbalance and the RAAS in early pregnancy is required.

The higher urinary AGT concentrations seen in women with PE could be related to renally synthesized AGT, which spills over into the urine, where it can be measured. Importantly, this suggests the potential local action of intrarenally generated Ang II, capable of fine-tuning intrarenal sodium reabsorption, and highlights the potential importance of examining the intra-renal RAAS, as well as the circulating RAAS when considering the origin of hypertension. This is supported by our recent reports of the presence of AGT expression in kidney biopsies collected from pregnant women \[[@sfz025-B46]\]. This finding requires further work, especially as studies into intra-renal AGT in human pregnancy are only just beginning to appear \[[@sfz025-B47]\]. Unlike women with PE without pre-existing disease, urinary AGT concentrations were the same in women with CKD with or without SPE, and considerably lower in both than in either group with normal renal function ([Figure 1](#sfz025-F1){ref-type="fig"}). This was unexpected since non-pregnant patients with CKD have been reported to have increased urinary AGT excretion (e.g. \[[@sfz025-B48]\]). It may be that pre-existing hypertension blunts the necessary response of renal AGT synthesis to pregnancy, which could contribute to the inadequate plasma volume expansion seen in pregnant women with chronic hypertension \[[@sfz025-B35]\]. The reduced urinary TH-aldo: urine AGT ratio in PE women suggests a disruption of the RAAS system as the increased AGT is not linked to higher aldosterone concentrations.

The absence of differences in plasma AGT concentrations between groups may be due to quantification of total AGT rather than oxidized and reduced forms separately, which have been shown to be different between NCs and PE \[[@sfz025-B49]\]. In addition, others have reported that high-molecular mass AGT is a complex eosinophil major basic protein (proMBP) with normal AGT \[[@sfz025-B50]\]. It has been reported that the kinetics of cleavage by renin of proMBP-AGT are impaired and may contribute to the reduced renin concentrations observed in PE \[[@sfz025-B51]\].

This study was restricted to samples from White European women due to the known differences in the RAAS in Afro-Caribbean women \[[@sfz025-B25]\]. A detailed analysis was restricted to samples from White European women due to the known differences in the RAS in Afro-Caribbean women, of which there were only a small number of samples, and thus were excluded.

A limitation of the study includes the challenge of confirming the diagnosis of SPE in women with CKD; however, confirmation of diagnosis by two independent adjudicators and pre-specified diagnosis criteria reduced this uncertainty. This further emphasizes the need to find other more suitable tools.

In conclusion, the findings of this study allow us to propose that reduced PlGF concentrations (and thus reduced translocation of the VEGF to the active receptor, secondary to increased sFlt-1) in women who develop PE, including SPE, is associated with reduced renin synthesis and also less VEGF-derived adrenal aldosterone synthesis, which in turn results in lower urinary aldosterone concentrations. Renin activity and aldosterone synthesis are dissociated in pregnancy \[[@sfz025-B52]\] and AGT concentrations become rate-limiting for Ang II production \[[@sfz025-B53]\]. Ang II thus cannot be adequately upregulated with secondary increase in aldosterone in response to plasma volume reduction in PE. Furthermore, these data suggest urinary TH-aldo:creatinine ratios and plasma active renin in addition to PlGF may be useful discriminators between pre-existing CKD and SPE.
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